1. Home
  2. OLMA vs SSBK Comparison

OLMA vs SSBK Comparison

Compare OLMA & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • SSBK
  • Stock Information
  • Founded
  • OLMA 2006
  • SSBK 2007
  • Country
  • OLMA United States
  • SSBK United States
  • Employees
  • OLMA N/A
  • SSBK N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • SSBK Commercial Banks
  • Sector
  • OLMA Health Care
  • SSBK Finance
  • Exchange
  • OLMA Nasdaq
  • SSBK Nasdaq
  • Market Cap
  • OLMA 289.0M
  • SSBK N/A
  • IPO Year
  • OLMA 2020
  • SSBK 2021
  • Fundamental
  • Price
  • OLMA $4.67
  • SSBK $35.53
  • Analyst Decision
  • OLMA Strong Buy
  • SSBK Buy
  • Analyst Count
  • OLMA 3
  • SSBK 1
  • Target Price
  • OLMA $27.67
  • SSBK $36.00
  • AVG Volume (30 Days)
  • OLMA 902.4K
  • SSBK 41.8K
  • Earning Date
  • OLMA 05-16-2025
  • SSBK 04-21-2025
  • Dividend Yield
  • OLMA N/A
  • SSBK 1.01%
  • EPS Growth
  • OLMA N/A
  • SSBK 6.02
  • EPS
  • OLMA N/A
  • SSBK 3.80
  • Revenue
  • OLMA N/A
  • SSBK $99,026,000.00
  • Revenue This Year
  • OLMA N/A
  • SSBK $19.18
  • Revenue Next Year
  • OLMA N/A
  • SSBK $7.05
  • P/E Ratio
  • OLMA N/A
  • SSBK $9.36
  • Revenue Growth
  • OLMA N/A
  • SSBK 18.43
  • 52 Week Low
  • OLMA $2.86
  • SSBK $24.86
  • 52 Week High
  • OLMA $16.62
  • SSBK $39.16
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 50.50
  • SSBK 63.53
  • Support Level
  • OLMA $4.35
  • SSBK $34.44
  • Resistance Level
  • OLMA $5.74
  • SSBK $35.37
  • Average True Range (ATR)
  • OLMA 0.40
  • SSBK 0.74
  • MACD
  • OLMA -0.02
  • SSBK 0.28
  • Stochastic Oscillator
  • OLMA 25.26
  • SSBK 93.37

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: